Benzinga | Mar 26, 2021 07:31AM EDT

Acerus Pharma Amended Existing Credit Facility With SWK Funding To Set Principal Repayment At $1.1M For May 15, 2021, Qtr. Repayments At $600K For Aug. 15, 2021

Acerus Pharmaceuticals Corporation ("Acerus" or the "Company") (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into an amended agreement related to its existing credit facility with SWK Funding LLC ("SWK"), a subsidiary of SWK Holdings Corporation (NASDAQ:SWKH).

The nature of the amendments are to: i) set principal repayment at US$1.1 million for May 15, 2021 followed by quarterly principal repayments of US$600,000 effective August 15, 2021 and thereafter; ii) adjust the minimum threshold for Consolidated Unencumbered Liquid Assets (as defined in the credit facility as cash adjusted for certain portions of accounts receivable and accounts payable) required to be maintained by the Company at US$2.0 million effective May 15, 2021; iii) remove all revenue and Adjusted EBITDA covenants for the balance of 2021; and iv) adjust revenue and Adjusted EBITDA covenants for 2022 and onward.

All other terms and conditions in the SWK credit facility remain unchanged.